ATE311226T1 - Die glycin-betain für seine antithrombotische verwendung - Google Patents

Die glycin-betain für seine antithrombotische verwendung

Info

Publication number
ATE311226T1
ATE311226T1 AT00907365T AT00907365T ATE311226T1 AT E311226 T1 ATE311226 T1 AT E311226T1 AT 00907365 T AT00907365 T AT 00907365T AT 00907365 T AT00907365 T AT 00907365T AT E311226 T1 ATE311226 T1 AT E311226T1
Authority
AT
Austria
Prior art keywords
glycine
betain
antithrombotic
antithrombotic use
glycine betain
Prior art date
Application number
AT00907365T
Other languages
English (en)
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jallal Messadek filed Critical Jallal Messadek
Application granted granted Critical
Publication of ATE311226T1 publication Critical patent/ATE311226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00907365T 1999-03-02 2000-03-01 Die glycin-betain für seine antithrombotische verwendung ATE311226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9900144A BE1012495A3 (fr) 1999-03-02 1999-03-02 La glycine-betaine pour son usage antithrombotique.
PCT/BE2000/000021 WO2000051596A1 (fr) 1999-03-02 2000-03-01 La glycine betaïne pour son usage antithrombotique

Publications (1)

Publication Number Publication Date
ATE311226T1 true ATE311226T1 (de) 2005-12-15

Family

ID=3891794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907365T ATE311226T1 (de) 1999-03-02 2000-03-01 Die glycin-betain für seine antithrombotische verwendung

Country Status (20)

Country Link
US (1) US6855734B2 (de)
EP (1) EP1156796B1 (de)
JP (1) JP2002538113A (de)
KR (1) KR100767270B1 (de)
CN (1) CN1194681C (de)
AT (1) ATE311226T1 (de)
AU (1) AU2897900A (de)
BE (1) BE1012495A3 (de)
BR (1) BR0008631A (de)
CA (1) CA2362558C (de)
DE (1) DE60024415T2 (de)
EA (1) EA004047B1 (de)
ES (1) ES2254144T3 (de)
HK (1) HK1044276B (de)
HU (1) HUP0105397A3 (de)
IL (1) IL145068A0 (de)
MX (1) MXPA01008426A (de)
NZ (1) NZ513905A (de)
PL (1) PL204560B1 (de)
WO (1) WO2000051596A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
CA2441948A1 (en) * 2001-02-05 2002-08-15 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
CA2477245A1 (en) * 2002-02-25 2003-09-04 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP1569692B1 (de) * 2002-11-25 2010-11-10 Jallal Messadek Betain und Salicylsäure Zusammensetzungen
US8697679B2 (en) 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
CA2575760A1 (en) * 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
EP2540696B1 (de) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans-Karotinoide, deren Formulierung und Verwendung
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
KR20100083820A (ko) * 2007-10-31 2010-07-22 디퓨젼 파마슈티컬즈 엘엘씨 저분자 확산을 촉진시키는 신규한 치료요법
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
EP2445339B1 (de) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Verteilungsverbessernde verbindung und ihre verwendung mit einem thrombolytikum
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
CN109342606B (zh) * 2018-12-05 2021-11-02 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种水产品中甘氨酸甜菜碱的检测方法
US11285349B1 (en) * 2019-10-07 2022-03-29 TFS Holdings, LLC Sprinkler system antifreeze compositions and methods
CN111505131B (zh) * 2020-01-02 2023-03-31 东莞东华医院有限公司 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980277A (en) * 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
EP0347864A3 (de) * 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Antiatherosklerose-Mittel
WO1995015750A1 (en) * 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11727B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6162852A (en) 1996-12-13 2000-12-19 Isolyser Company, Inc. Degradable polymers

Also Published As

Publication number Publication date
DE60024415D1 (de) 2006-01-05
CN1194681C (zh) 2005-03-30
BR0008631A (pt) 2002-02-13
CA2362558C (fr) 2009-06-02
HK1044276A1 (en) 2002-10-18
EP1156796A1 (de) 2001-11-28
IL145068A0 (en) 2002-06-30
ES2254144T3 (es) 2006-06-16
HK1044276B (zh) 2006-12-22
NZ513905A (en) 2001-09-28
WO2000051596A9 (fr) 2001-10-11
PL350408A1 (en) 2002-12-02
HUP0105397A2 (hu) 2002-05-29
BE1012495A3 (fr) 2000-11-07
CN1342071A (zh) 2002-03-27
AU2897900A (en) 2000-09-21
CA2362558A1 (fr) 2000-09-08
KR100767270B1 (ko) 2007-10-17
DE60024415T2 (de) 2006-09-21
HUP0105397A3 (en) 2003-03-28
WO2000051596A1 (fr) 2000-09-08
PL204560B1 (pl) 2010-01-29
JP2002538113A (ja) 2002-11-12
EA200100925A1 (ru) 2002-04-25
KR20020021369A (ko) 2002-03-20
MXPA01008426A (es) 2003-06-06
US6855734B2 (en) 2005-02-15
EP1156796B1 (de) 2005-11-30
US20020065320A1 (en) 2002-05-30
EA004047B1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
ATE311226T1 (de) Die glycin-betain für seine antithrombotische verwendung
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
DK1220852T3 (da) Substituerede diazepaner
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DK1532131T3 (da) Motilid-forbindelser
TR200200278T2 (tr) Kalsilitik bileşimler
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE330604T1 (de) Behandlung von manischen erkrankungen
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156796

Country of ref document: EP

REN Ceased due to non-payment of the annual fee